Sentence examples for molecular remission increased from inspiring English sources

Ahmad et al. reported that CD34+ expression was significantly associated with decreased incidence of molecular remission, increased incidence of early death, and higher WBC count [ 1].

Sustained remission was only and mainly determined by time-to-remission; the chance of sustained remission increased significantly with decreasing time-to-remission.

The frequencies of remission increased from 6 months and onwards by all criteria used.

The interacting variable identified six levels of progressively higher exposure to remission (increasing number/decreasing timing): remission once at year 1, 2 and 3, remission twice with first remission at year 1 or 2 and three times in remission.

A number of studies have demonstrated an increase in molecular remission using rituximab post-transplant (Horwitz et al, 2001; Brugger et al, 2002), but it remains to be seen whether these translate into durable clinical remissions.

An increase in molecular remission was observed after rituximab consolidation in both chemotherapy groups, from 20 to 40% in the CHOP group and from 34 to 59% in the FM group.

Rituximab-containing chemotherapy regimens appear to increase both clinical and molecular remission rates when compared with those usually achieved with chemotherapy only, giving grounds for optimism that they may also result in improved PFS.

Complete molecular remission was noted in patients 3 and 4, and increased circulating PR1-CTL persisted during the study period (12 15 months).

A subset of allo-SCT patients showed persistent molecular remission.

There was no evidence of GVHD and the patients were in molecular remission 12 months after therapy (Qasim et al., 2017).

In that study, PR1-CTL immunity was not assessed in two patients that achieved complete molecular remission in IFN maintenance.